Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisporivir plus ribavirin dose-regimen comparison in chronic hepatitis C genotype 2/3 after interferon failure or intolerance
2013-003751-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alisporivir in hepatitis C virus infection (2 arms), sponsored by Novartis. Primary endpoint: Viral load drop from baseline through week 12. Started Jun 2015; status: completed.
02
Drugs
alisporivir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-003751-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003751-38.